Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study.
Kano. Toshiko T; Sugihara. Hitoshi H; Sudo. Mariko M; Nagao. Mototsugu M; Harada. Taro T; Ishizaki. Akira A; Nakajima. Yasushi Y; Tanimura. Kyouko K; Okajima. Fumitaka F; Tamura. Hideki H; Ishii. Shinya S; Shibasaki. Tamotsu T; Oikawa. Shinichi S
Key Findings
- GHRP‑2 (100 µg IV) triggers a cortisol response that correlates strongly with the ITT response (r=0.817).
- Patients with normal adrenal function showed median peak cortisol ~21.4 µg/dL, while those with failure showed ~11.4 µg/dL after GHRP‑2.
- A cortisol cut‑off of 13‑14 µg/dL after GHRP‑2 gave 100% specificity and 88.9% sensitivity for detecting adrenal insufficiency.
Practical Outcomes
- For biohackers, GHRP‑2 might become a less stressful test for adrenal health compared to the risky ITT, but it currently requires IV administration and clinical‑grade labs. Until larger studies and easier delivery methods (e.g., sub‑Q) are available, it’s more of a proof‑of‑concept than a ready‑to‑use home protocol.
Summary
This small study shows that giving a single IV dose of the peptide GHRP‑2 can raise cortisol levels in a way that closely matches the traditional insulin tolerance test (ITT), which is the gold‑standard for checking adrenal (HPA‑axis) health. A cortisol level of about 13‑14 µg/dL after GHRP‑2 reliably flags adrenal failure, suggesting the peptide could be a simpler way to assess this system, though the research is still early and done in a clinical setting.
Abstract
Insulin tolerance test (ITT) is the gold standard for assessing the hypothalamic-pituitary-adrenal (HPA) function. GH-releasing peptide (GHRP)-2, which has a strong GH-stimulating activity, is useful for diagnosing GH deficiency as well as ITT. Additionally, GHRP-2 is also known to activate HPA axis. There have been no comparative studies of pituitary-adrenal responsiveness between GHRP-2 test and ITT in patients with hypothalamic/pituitary disease. To assess whether GHRP-2 test could be an alternative to ITT for diagnosing HPA axis failure, both ITT and GHRP-2 test were performed in 15 patients suspected of hypopituitarism. A 100mug dose of GHRP-2 was administered intravenously and plasma ACTH and serum cortisol concentrations were measured. In ITT, a peak cortisol value over 18mug/dl is considered normal. Nine patients were diagnosed as HPA axis failure by ITT. Their median peak cortisol in GHRP-2 test was 11.4mug/ml. In 6 patients diagnosed as normal HPA axis status by ITT, their median peak cortisol in response to GHRP-2 test was 21.4mug/dl, significantly higher (p=0.0032) than seen in patients diagnosed as HPA axis failure. There was a strong correlation between the peak cortisol in GHRP-2 test and ITT (r=0.817; p<0.0001). When the cut-off value for the peak cortisol in GHRP-2 test was set to 13-14mug/dl for diagnosing HPA axis failure, the specificity and sensitivity were 100% and 88.9%, respectively. Although further studies that include normal subjects are needed, these preliminary results suggest the possibility that GHRP-2 test may be an alternative to ITT for assessing HPA axis function.
Study Information
pubmed
2010
2010-01-05T00:00:00.000Z
10.1016/j.peptides.2009.12.023
9
24